Prescient Therapeutics Revenue

Prescient Therapeutics had revenue of 1.16M AUD in the half year ending December 31, 2025, a decrease of -40.31%. This brings the company's revenue in the last twelve months to 4.27M, up 41.20% year-over-year. In the fiscal year ending June 30, 2025, Prescient Therapeutics had annual revenue of 4.36M with 17.35% growth.

Revenue (ttm)

4.27M

Revenue Growth

+41.20%

P/S Ratio

13.56

Revenue / Employee

1.42M

Employees

Market Cap

57.83M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2025	4.36M	644.03K	17.35%
Jun 30, 2024	3.71M	1.28M	52.89%
Jun 30, 2023	2.43M	538.79K	28.52%
Jun 30, 2022	1.89M	703.86K	59.37%
Jun 30, 2021	1.19M	156.14K	15.17%
Jun 30, 2020	Pro	Pro	Pro
Jun 30, 2019	Pro	Pro	Pro
Jun 30, 2018	Pro	Pro	Pro
Jun 30, 2017	Pro	Pro	Pro
Jun 30, 2016	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Neurizon Therapeutics	5.98M
Amplia Therapeutics	5.01M
Proteomics International Laboratories	3.21M
Radiopharm Theranostics	16.28M
Entropy Neurodynamics	1.58M
Imugene	3.94M
Alterity Therapeutics	6.64M
EZZ Life Science Holdings	61.40M

Revenue Rankings

Prescient Therapeutics News

3 months ago - Prescient Therapeutics Limited (PSTTF) Discusses EMA Orphan Drug Designation and Clinical Progress of PTX-100 for CTCL Transcript - Seeking Alpha
5 months ago - Prescient Therapeutics Limited (PSTTF) Discusses Clinical Progress of PTX-100 in Cancer Trials and Regulatory Milestones Transcript - Seeking Alpha
5 months ago - Prescient Therapeutics Limited (PSTTF) Shareholder/Analyst Call Transcript - Seeking Alpha

More News